
Please try another search
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Name | Age | Since | Title |
---|---|---|---|
Jane F. Barlow | 60 | 2021 | Independent Director |
Lishan Aklog | 55 | 2020 | Independent Director |
Cary William Sucoff | 69 | 2010 | Independent Director |
Vincent A. Fischetti | - | - | Chairman of Scientific Advisory Board |
Peter Palese | - | - | Member of Scientific Advisory Board |
Sol J. Barer | 74 | 2011 | Lead Independent Director |
Adolfo Garcia-Sastre | - | - | Member of Scientific Advisory Board |
Leon G. Smith | - | - | Member of Scientific Advisory Board |
David N. Low | 62 | 2014 | Independent Director |
Steven C. Gilman | 68 | 2015 | Vice Chairman |
Roger James Pomerantz | 64 | 2014 | Chairman, CEO & President |
Daniel J. Capon | - | - | Member of Scientific Advisory Board |
Michael J. Otto | 72 | 2014 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review